dapsone has been researched along with amg531 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diez-Ewald, M; Vizcaíno, G; Vizcaíno-Carruyo, J | 1 |
| Audia, S; Bonnotte, B; Godeau, B | 1 |
| Aboud, N; Depré, F; Mayer, B; Salama, A | 1 |
1 review(s) available for dapsone and amg531
| Article | Year |
|---|---|
[Treatment of chronic immune thrombocytopenic purpura. Looking for something better. Review].
Topics: Adrenal Cortex Hormones; Antigens, Human Platelet; Autoantibodies; Benzoates; Blood Platelets; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Dapsone; Helicobacter Infections; Helicobacter pylori; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Models, Immunological; Molecular Mimicry; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy; Thrombopoiesis | 2009 |
2 other study(ies) available for dapsone and amg531
| Article | Year |
|---|---|
Is there still a place for "old therapies" in the management of immune thrombocytopenia?
Topics: Benzoates; Danazol; Dapsone; Humans; Hydrazines; Hydroxychloroquine; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thrombopoietin; Vinca Alkaloids | 2016 |
Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Benzoates; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Dapsone; Dexamethasone; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Remission Induction; Retrospective Studies; Rho(D) Immune Globulin; Rituximab; Splenectomy; Thrombopoietin; Treatment Outcome; Young Adult | 2018 |